Sustainability News
-
ASKA Selected as Excellent Company for the Second Consecutive Year in “Gomez ESG Web Awards 2026”
-
Support for Victims of the 2026 Kumamoto Earthquake
-
Added "Build Muscle for the Future: Exercises for Those Concerned About Declining Physical Strength" to Mint+ Exercise.(Japanese version only)
-
ESG Data Book 2026 is now available
-
We have added “Don't Miss It! Understanding Thyroid Disorders” to the Mint⁺ Women's Health Lab series, “What Every Woman Should Know About Her Body and Health.” (Japanese version only)
Sustainability Sitemap
ASKA Pharmaceutical Holdings in Numbers
-
Promotion of Women's advancement
-
Ratio of female
employees*134.7% -
Ratio of female
management positions14.3% -
Ratio of female
management
candidates20.7%
(End of FY2025 in ASKA Pharmaceutical)
-
-
Ratio of male employees taking child care leave
100.0%(FY2025 in ASKA Pharmaceutical)
-
Reduction rate of Total CO₂ Emissions
55.3%* The rate in FY2025 compared with the rate in FY2013
Our Sustainability
Initiatives for ESG
-
Environment
Environmental
The Group is committed to protecting the environment and reducing its impact across all areas of its business, contributing to resolving global environmental issues and realizing a sustainable society.
-
Social
Social
The Group's belief is that they should not only provide superior pharmaceutical products through their business activities but also recognize and contribute to solving various issues as a responsible member of society. Moreover, the Company intends to actively participate in social contribution activities as a good corporate citizen, apart from contributing to society through their business activities.
-
Sustainability Governance
Sustainability Governance
The Group's objective is to attain sustainable growth for the Company and its subsidiaries while improving its corporate value in the medium to long term. To achieve this goal, the Group is consistently working on establishing and reinforcing a robust and influential corporate governance system.
ESG Data & Library
Integrated Report
ASKA HD REPORT 2025
Download individually ASKA HD REPORT2025 Contents
- Introduction
- Value Creation Story
-
- 13_History of Value Creation
- 17_At a Glance
- 19_The Foundation for Our Path Forward
- 21_Message from the Chairman
- 23_Message from the President
- 27_Value Creation Process
- 29_Capital and Strengths
- 31_Current Business Climate
- 33_Material Issues
- 37_Featured Dialogue:The Importance of Women’s Healthcare and Addressing Social Issues
- Explanation of Strategy
-
- 41_ASKA Pharmaceutical Holdings’ Medium-Term Management Plan 2025
- 43_ASKA Pharmaceutical
- 48_Ha Tay Pharmaceutical Joint Stock Company
- 49_ASKA Animal Health
- 51_ASKA Pharma Medical
- 53_Financial and Capital Strategy
- 57_Manufactured Capital and Intellectual Capital Strategies
- 62_Natural Capital Strategy
- 67_Social Capital Strategy
- 71_Human Capital Strategy
- Foundation for Value Creation
- Data Section
For Those Who Wish to Receive a Printed Copy of the Integrated Report (Available in Japan Only)
If you would like to receive a printed copy of the Integrated Report, please submit your request using the link button on the right.
Inquiries about our sustainability
For inquiries for our sustainability, please use the following telephone or inquiry form.
*Depending on the content of your inquiry, we may not be able to reply.